Yijun Bao Cheng

Prof. Yijun Bao Cheng

orcid

Research Focus & Metrics

Representative Publications

View All Publications
9 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
YCYijun Bao Cheng
Yijun Bao Cheng
DWDapeng Wang
Dapeng Wang
HTHao Tang
Hao Tang
DTDebing Tong
Debing Tong
WZWeiguo Zhao
Weiguo Zhao
ZWZhe Bao Wu
Zhe Bao Wu
Several subtypes of pituitary neuroendocrine tumors (PitNETs), such as acromegaly and Cushing’s disease, can result in hypertension. However, whether prolactinoma is associated with this complication remains unknown. Moreover, the effect of treatment with surgery or drugs on blood pressure (BP) is unknown. Herein, a retrospective study reviewed 162 patients with prolactinoma who underwent transsphenoidal surgery between January 2005 and December 2022. BP measurements were performed 1 day before and 5 days after surgery. Accordingly, patients’ medical characteristics were recorded. In addition, in situ rat and xenograft nude-mice prolactinoma models have been used to mimic prolactinoma. In vivo BP and serum prolactin (PRL) levels were measured after cabergoline (CAB) administration in both rats and mice. Our data suggest that surgery can effectively decrease BP in prolactinoma patients with or without hypertension. The BP-lowering effect was significantly associated with several variables, including age, sex, disease duration, tumor size, invasion, dopamine agonists (DAs)-resistance, recurrence, and preoperative PRL levels. Moreover, in situ and xenograft prolactinomas induced BP elevation, which was alleviated by CAB treatment without and with a statistical difference in rats and mice, respectively. Thus, surgery or CAB can decrease BP in prolactinoma, indicating that pre- and postoperative BP management becomes essential.

21 January 2026 in Endocrine
Verified
Journal Article
Closed access
PDF file
YCYijun Bao Cheng
Yijun Bao Cheng
YWYu Wang
Yu Wang
WLWenwen Lv
Wenwen Lv
GYGang Yang
Gang Yang
YZYazhuo Zhang
Yazhuo Zhang
ZWZhe Bao Wu
Zhe Bao Wu

7 February 2026 in Journal of Controlled Release
Verified
Journal Article
Closed access
YGYuxuan Ge
Yuxuan Ge
FRFan Rong
Fan Rong
ZWZixin Wang
Zixin Wang
YLYujia Lu
Yujia Lu
YZYanwen Zhang
Yanwen Zhang
Yin WangYin Wang
Yin Wang

6 June 2022 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
YCYijun Bao Cheng
Yijun Bao Cheng
HTHao Tang
Hao Tang
ZWZhe Bao Wu
Zhe Bao Wu
HSHanbing Shang
Hanbing Shang

13 August 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
GYGe Yuxuan
Ge Yuxuan
FRFan Rong
Fan Rong
ZWZixin Wang
Zixin Wang
YLYujia Lu
Yujia Lu
YZYanwen Zhang
Yanwen Zhang
Yin WangYin Wang
Yin Wang
Gouty arthritis (GA) is a common arthritis characterized by abnormal deposition of monosodium urate (MSU) crystals in articular structures. Current clinical medications can only alleviate the inflammation caused by the acute GA temporarily, but have no solution to the deposition of MSU. To surmount this, urate oxidase (UOx) was initially modified with the phenylboronic acid-based self-immolative thiocarbamate through nucleophilic substitution, and then co-assembled with curcumin through boronate bond to form the platform (termed UBC). This way, the platform could not only directly eliminate the MSU, but also release the therapeutic gas hydrogen sulfide (H2S) triggered by the toxic by-product of UOx catalysis, hydrogen peroxide (H2O2). Synergized with curcumin, the inflammation could be effectively suppressed. In vivo experiments on an acute GA murine model also validated the potent therapeutic effect of the platform, mainly due to the synergistic effect of H2S and curcumin. We believe this strategy provides a novel approach for the treatment of inflammation-related diseases and novel insight into the construction of multi-functional therapeutic nanomaterials from enzymes and other biomolecules.